BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27888093)

  • 21. Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience.
    Yang JW; Wang JN; Men TY; Zhang XM; Li XD; Shen B; Li GY; Chen DD
    Ann Transplant; 2014 Jun; 19():277-82. PubMed ID: 24906405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation.
    Sageshima J; Ciancio G; Guerra G; Gaynor JJ; Cova D; Zarak A; Chen L; Mattiazzi A; Kupin W; Roth D; Hanson L; Livingstone AS; Ruiz P; Burke GW
    Transpl Immunol; 2011 Sep; 25(2-3):104-11. PubMed ID: 21784152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
    Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients.
    Pennington CA; Tischer SM; Lee E; Lee S; Sindelar J; Park JM
    Pharmacotherapy; 2015 Aug; 35(8):748-54. PubMed ID: 26234282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial of three induction antibodies in kidney transplantation: long-term results.
    Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Chen L; Mattiazzi A; Roth D; Kupin W; Tueros L; Flores S; Hanson L; Vianna R; Burke GW
    Transplantation; 2014 Jun; 97(11):1128-38. PubMed ID: 24477186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
    Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
    Morgan RD; O'Callaghan JM; Knight SR; Morris PJ
    Transplantation; 2012 Jun; 93(12):1179-88. PubMed ID: 22660659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction therapy in renal transplant recipients: how convincing is the current evidence?
    Wagner SJ; Brennan DC
    Drugs; 2012 Mar; 72(5):671-83. PubMed ID: 22439670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis.
    Ciancio G; Gaynor JJ; Zarak A; Sageshima J; Guerra G; Roth D; Brown R; Kupin W; Chen L; Tueros L; Hanson L; Ruiz P; Burke GW
    Transplantation; 2011 Jun; 91(11):1198-205. PubMed ID: 21107305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Induction Therapy in Kidney Transplantation: A Network Meta-Analysis.
    Hwang SD; Lee JH; Lee SW; Park KM; Kim JK; Kim MJ; Song JH
    Transplant Proc; 2018 May; 50(4):987-992. PubMed ID: 29731098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-year outcomes with alemtuzumab induction after lung transplantation.
    Shyu S; Dew MA; Pilewski JM; DeVito Dabbs AJ; Zaldonis DB; Studer SM; Crespo MM; Toyoda Y; Bermudez CA; McCurry KR
    J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
    Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients.
    Palanisamy AP; Al Manasra AR; Pilch NA; Dowden JE; Nadig SN; McGillicuddy JW; Baliga PK; Chavin KD; Taber DJ
    Clin Transplant; 2015 Mar; 29(3):222-6. PubMed ID: 25557762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
    Sampaio MS; Chopra B; Sureshkumar KK
    Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early outcomes comparing induction with antithymocyte globulin vs alemtuzumab in two steroid-avoidance protocols in pediatric renal transplantation.
    Puliyanda DP; Pizzo H; Rodig N; Somers MJG
    Pediatr Transplant; 2020 May; 24(3):e13685. PubMed ID: 32112514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal transplantation in the setting of early steroid withdrawal: a comparison of rabbit antithymocyte globulin induction dosing in two eras.
    Rogers CC; Asipenko N; Horwedel T; Gautam S; Goldfarb-Rumyantzev AS; Pavlakis M; Johnson SR; Karp SJ; Evenson A; Khwaja K; Hanto DW; Mandelbrot DA
    Am J Nephrol; 2013; 38(5):397-404. PubMed ID: 24192457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation.
    Koyawala N; Silber JH; Rosenbaum PR; Wang W; Hill AS; Reiter JG; Niknam BA; Even-Shoshan O; Bloom RD; Sawinski D; Nazarian S; Trofe-Clark J; Lim MA; Schold JD; Reese PP
    J Am Soc Nephrol; 2017 Jul; 28(7):2188-2200. PubMed ID: 28320767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of small variations in the delivered dose of rabbit antithymocyte induction therapy in kidney transplantation with early corticosteroid withdrawal.
    Tsapepas DS; Mohan S; Tanriover B; Dube G; Crew RJ; Cohen DJ; Hardy MA; Sandoval PR; Ratner LE
    Transplantation; 2012 Aug; 94(4):325-30. PubMed ID: 22814328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report.
    Stevens RB; Mercer DF; Grant WJ; Freifeld AG; Lane JT; Groggel GC; Rigley TH; Nielsen KJ; Henning ME; Skorupa JY; Skorupa AJ; Christensen KA; Sandoz JP; Kellogg AM; Langnas AN; Wrenshall LE
    Transplantation; 2008 May; 85(10):1391-9. PubMed ID: 18497677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.